CW September 2006
Volume 15Issue Number 9 September 2006 ISSN 10593802 Imatinib and Other Tyrosine Kinase Inhibitors Offer More Options to Treat Chronic Myelogenous LeukemiaPrimary therapy with imatinib, second-line therapy with dasatinib, and new oral agents such as nilotinib are changing the course of treatment of chronic myelogenous leukemia (CML) by offering more options to more patients.
Go to Previous Page Go to Next Page Source & Additional Reading H. P. Erba, presented at the 2006 American Society of Clinical Oncology Annual Meeting. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW September 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
